...
allr-img

Allarity Therapeutics Inc, Common Stock

ALLR

NAQ

$1.056

+$0.09

(9.28%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.87M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.9 L
$373.8 H
$1.056

About Allarity Therapeutics Inc, Common Stock

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALLRSectorS&P500
1-Week Return-7.61%-3.39%-3.47%
1-Month Return-19.83%-3.25%-0.29%
3-Month Return-57.82%-11.61%4.5%
6-Month Return-92.67%-5.89%6.91%
1-Year Return-99.7%2.65%23.79%
3-Year Return-100%0.56%28.43%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue120.00K----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-86.00K106.00K120.00K37.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":71.67,"profit":true},{"date":"2021-12-31","value":88.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":30.83,"profit":true}]
Gross Profit120.00K(86.00K)(106.00K)(120.00K)(37.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-71.67,"profit":false},{"date":"2021-12-31","value":-88.33,"profit":false},{"date":"2022-12-31","value":-100,"profit":false},{"date":"2023-12-31","value":-30.83,"profit":false}]
Gross Margin100.00%----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses10.24M9.23M26.56M16.89M17.89M[{"date":"2019-12-31","value":38.55,"profit":true},{"date":"2020-12-31","value":34.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":63.61,"profit":true},{"date":"2023-12-31","value":67.37,"profit":true}]
Operating Income(17.61M)(9.23M)(26.56M)(34.46M)(17.93M)[{"date":"2019-12-31","value":-1761100000,"profit":false},{"date":"2020-12-31","value":-922700000,"profit":false},{"date":"2021-12-31","value":-2655600000,"profit":false},{"date":"2022-12-31","value":-3446300000,"profit":false},{"date":"2023-12-31","value":-1792900000,"profit":false}]
Total Non-Operating Income/Expense(4.67M)1.67M(1.80M)(880.00K)4.96M[{"date":"2019-12-31","value":-94.23,"profit":false},{"date":"2020-12-31","value":33.75,"profit":true},{"date":"2021-12-31","value":-36.41,"profit":false},{"date":"2022-12-31","value":-17.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(18.98M)(7.23M)(26.52M)(17.58M)(12.62M)[{"date":"2019-12-31","value":-1897700000,"profit":false},{"date":"2020-12-31","value":-723400000,"profit":false},{"date":"2021-12-31","value":-2651500000,"profit":false},{"date":"2022-12-31","value":-1757900000,"profit":false},{"date":"2023-12-31","value":-1261800000,"profit":false}]
Income Taxes(4.58M)(2.16M)133.00K(1.52M)(717.00K)[{"date":"2019-12-31","value":-3441.35,"profit":false},{"date":"2020-12-31","value":-1624.81,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1143.61,"profit":false},{"date":"2023-12-31","value":-539.1,"profit":false}]
Income After Taxes(14.40M)(5.07M)(26.65M)(16.06M)(11.90M)[{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1190100000,"profit":false}]
Income From Continuous Operations(14.40M)(5.07M)(26.65M)(16.06M)(13.02M)[{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1301700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(14.40M)(5.07M)(26.65M)(16.06M)(11.90M)[{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1190100000,"profit":false}]
EPS (Diluted)(0.28)(0.04)(1.00M)(18.53)(29.23)[{"date":"2019-12-31","value":-27.61,"profit":false},{"date":"2020-12-31","value":-4.08,"profit":false},{"date":"2021-12-31","value":-100000101.68,"profit":false},{"date":"2022-12-31","value":-1853,"profit":false},{"date":"2023-12-31","value":-2923,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALLR
Cash Ratio 2.49
Current Ratio 2.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALLR
ROA (LTM) -47.72%
ROE (LTM) -121.82%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALLR
Debt Ratio Lower is generally better. Negative is bad. 0.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.64

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALLR
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.38
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Allarity Therapeutics Inc share price today?

Allarity Therapeutics Inc (ALLR) share price today is $1.056

Can Indians buy Allarity Therapeutics Inc shares?

Yes, Indians can buy shares of Allarity Therapeutics Inc (ALLR) on Vested. To buy Allarity Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALLR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Allarity Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Allarity Therapeutics Inc (ALLR) via the Vested app. You can start investing in Allarity Therapeutics Inc (ALLR) with a minimum investment of $1.

How to invest in Allarity Therapeutics Inc shares from India?

You can invest in shares of Allarity Therapeutics Inc (ALLR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALLR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Allarity Therapeutics Inc shares
What is Allarity Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Allarity Therapeutics Inc (ALLR) is $373.8. The 52-week low price of Allarity Therapeutics Inc (ALLR) is $0.9.

What is Allarity Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Allarity Therapeutics Inc (ALLR) is

What is Allarity Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Allarity Therapeutics Inc (ALLR) is 0.38

What is Allarity Therapeutics Inc dividend yield?

The dividend yield of Allarity Therapeutics Inc (ALLR) is 0.00%

What is the Market Cap of Allarity Therapeutics Inc?

The market capitalization of Allarity Therapeutics Inc (ALLR) is $2.06M

What is Allarity Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Allarity Therapeutics Inc is ALLR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top